CervoMed Inc.
No SEC Form 4 filings for $CRVO in the last 30 days.
See all $CRVO insider activity →CervoMed Inc. (CRVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA
CervoMed (CRVO) announced a new 50 mg tablet formulation for neflamapimod, meeting Phase 1 study objectives. The FDA removed a plasma drug exposure limit. The company plans a 100 mg twice-daily regimen for future trials, aiming to increase trough concentrations. CRVO stock closed at $2.54, up 0.79%.
CervoMed Inc. (CRVO) announced that initial results from its Phase 2a trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA) will be presented at the ISFTD Annual Meeting. The trial, involving 25 participants, aims to evaluate the safety and efficacy of neflamapimod, a drug targeting neuroinflammation and synaptic dysfunction. NfvPPA, a type of frontotemporal dementia, currently has no approved treatments in the U.S. or E.U.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CRVO (CervoMed Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent CRVO coverage spans technology, financial news and regulation.
The formulation and regulatory update de‑risk the program and improve dosing flexibility, likely supporting upside in CRVO.
The regulatory and formulation advances reduce CMC risk and support a higher‑dose BID regimen, improving the drug's commercial prospects.
Positive early biomarker read‑out could boost investor confidence and drive short‑term price appreciation ahead of the conference.
The designation de‑risks the UK launch and may boost the stock as investors price in accelerated market access.
The filing adds clinical and regulatory-development catalysts plus a financing runway update, but the key near-term variable is securing a Phase 3 partner.
AlphAI scores every news story that mentions CRVO with an AI model for sentiment and relevance, and aggregates insider trades from CervoMed Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CervoMed Inc. (CRVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA
2 min readCervoMed (CRVO) announced a new 50 mg tablet formulation for neflamapimod, meeting Phase 1 study objectives. The FDA removed a plasma drug exposure limit. The company plans a 100 mg twice-daily regimen for future trials, aiming to increase trough concentrations. CRVO stock closed at $2.54, up 0.79%.
2 min readCervoMed Inc. (CRVO) announced that initial results from its Phase 2a trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA) will be presented at the ISFTD Annual Meeting. The trial, involving 25 participants, aims to evaluate the safety and efficacy of neflamapimod, a drug targeting neuroinflammation and synaptic dysfunction. NfvPPA, a type of frontotemporal dementia, currently has no approved treatments in the U.S. or E.U.
2 min readCervoMed Inc. (CRVO) announced that its drug candidate, neflamapimod, received an Innovation Passport from the UK's ILAP for treating Dementia with Lewy Bodies (DLB). This designation accelerates regulatory review and market access in the UK, validating the drug's potential. The company is seeking a partner for Phase 3 trials and expects interim data from other trials in late 2026.
2 min readCervoMed Inc. (CRVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation und
6 min readCervoMed Inc. (NASDAQ: CRVO) reported at AAIC 2026 new Phase 2b analyses for neflamapimod in dementia with Lewy bodies. The company said results support selecting 50 mg TID for a planned Phase 3, citing effects on CDR-SB, plasma pTau181 exposure, and MRI basal forebrain atrophy/connectivity. It also reported Phase 2 data for 80 mg BID meeting safety and PK objectives.
6 min readCervoMed (NASDAQ: CRVO) said it completed enrollment in a Phase 2a trial of oral p38a inhibitor neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA). The study enrolled 25 patients and includes 24 weeks of dosing plus a 12-week randomized placebo-controlled extension. Interim biomarker data are slated for CTAD in Nov 2026, with first biomarker and clinical data expected Q4 2026 and Q1 2027.
2 min readCervoMed Inc. (CRVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ex_978640.htm EXHIBIT 4.1 ex_978640.htm Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FR
3 min readBOGER JOSHUA S purchased 955,414 indirectly-held shares of CervoMed Inc. (CRVO) at $3.14 ($3.00M total) on 2026-06-11.
2 min readCervoMed (NASDAQ: CRVO) said it entered a definitive agreement for a private placement expected to raise about $10.5 million in upfront gross proceeds, extending its cash runway into Q2 2027, according to the company. Funds will support a strategic partnership to advance neflamapimod into Phase 3 for dementia with Lewy bodies. Over six months, it expects Phase 2a 24-week biomarker/clinical data and to start EXPERTS-ALS Phase 2a.
6 min read
